PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

The Lens: Ophthalmology Research Newsletter on X: Check out our overview of the 2005 #MARINA study, for this week's #LensLandmarks! 👁️ The MARINA trial sought to determine the treatability of neovascular age-related

Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study, BMC Ophthalmology

JCM, Free Full-Text

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden - Gale - 2023 - Acta Ophthalmologica - Wiley Online Library

PDF) A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

PDF) A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration

Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study, BMC Ophthalmology

PDF) Six-year outcomes in neovascular age-related macular degeneration with ranibizumab